Volkswagen slid 2.7 per cent, pacing losses among carmakers, after ‘Manager Magazin’ said a drop in its Chinese deliveries could hurt earnings by more than €1 billion. Photograph: Krisztian Bocsi/Bloomberg

European stocks fell with miners and auto-related shares leading the plunge, extending their first weekly drop in three, as data around the world s(...)

Drugs that could be the “first” to slow the progression of Alzheimer’s disease have been unveiled on Wednesday. Researchers revealed the promising res(...)

 Traders on the floor of the New York Stock Exchange yesterday. Positive jobs reports sent the Dow Jones Industrial Average sharply higher. Photograph: Getty Images

European shares posted this year’s biggest advance, buoyed by a surprise election win for the British Conservative party and improving US jobs data.In(...)

In New York, Apple gave the biggest boost to the Nasdaq and the S&P 500 with a 1.2 per cent increase to $126.66. Photographer: Billy HC Kwok/Bloomberg

It was a quiet day of trading yesterday as most markets across continental Europe remained closed for the May Day holiday. The Iseq in Dub(...)

Revenue at Biogen rose about 20 per cent to $2.55 billion, missing Wall Street’s projections of $2.66 billion.

Biogen posted lower-then-expected quarterly profit and revenue as its key oral multiple sclerosis drug Tecfidera showed signs of slowing growth, send(...)

Domino’s Pizza: results out Thursday. Photograph: REUTERS/Luke MacGregor
For your diary

TODAY Results: Hasbro; M&T Bank; Morgan Stanley; Sanmina. Indicators: Euro zone construction output (Feb); US Chicago Fed national activity index (...)

Biogen’s market value has risen by $45 billion to nearly $110 billion in a little over a year

An experimental Alzheimer’s drug being developed by a US biotech group has offered hope that scientists may be closer to a breakthrough for the devast(...)

Denis Naughten, TD, believes Ireland should be a pilot country for State-funded multiple sclerosis drug. Photograph: Dara Mac Dónaill

The Health Service Executive has rejected a second application from the makers of a drug that helps people with multiple sclerosis to walk to have it(...)

Minister of State at the Department of Health Kathleen Lynch says Biogen’s new application is being assessed. Photograph: Eric Luke / The Irish Times

The makers of a drug that helps people with multiple sclerosis to walk have made a new application to have it covered by the Health Service Executi(...)

Although Fampridine, known commercially as Fampyra, is not covered by Health Service Executive-funded drug schemes, it has been provided free to patients for the past 2½ years under a clinical trial by the manufacturer, Biogen. Photograph: Biogen

Multiple sclerosis patients will have to pay up to €400 per month from today for a drug to improve mobility which was previously provided free of char(...)